NFKB1 and cancer: The NF-κB specific inhibitor DHMEQ, prevents the nuclear translocation of the transcription factor, and has been shown to have anti-cancer effects in numerous different cancer subtypes (Umezawa and Chaicharoenpong, 2002; Umezawa, 2006).